Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Myogenic and Osteogenic Responses to eXercise and Ibuprofen (MOXI)

This study has been completed.
Sponsor:
Collaborator:
National Institute on Aging (NIA)
Information provided by (Responsible Party):
University of Colorado, Denver
ClinicalTrials.gov Identifier:
NCT00462722
First received: April 17, 2007
Last updated: October 7, 2015
Last verified: October 2015
Results First Received: June 11, 2015  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Conditions: Aging
Physical Fitness
Interventions: Drug: Ibuprofen
Drug: Placebo
Behavioral: musculoskeletal-loading exercise

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Placebo Pre and Post Exercise

placebo before and after musculoskeletal-loading exercise

Placebo: with each exercise session (up to 5 days per week) for 9 months

musculoskeletal-loading exercise: Exercise training program designed to increase bone and muscle mass, including weight lifting and weight-bearing exercises such as jumping in place and treadmill walking up to 5 days per week for 9 months

Ibuprofen Pre and Placebo Post Exercise

ibuprofen before and placebo after musculoskeletal-loading exercise

Ibuprofen: 400 mg with each exercise session (up to 5 days per week) for 9 months

Placebo: with each exercise session (up to 5 days per week) for 9 months

musculoskeletal-loading exercise: Exercise training program designed to increase bone and muscle mass, including weight lifting and weight-bearing exercises such as jumping in place and treadmill walking up to 5 days per week for 9 months

Placebo Pre and Ibuprofen Post Exercise

placebo before and ibuprofen after musculoskeletal-loading exercise

Ibuprofen: 400 mg with each exercise session (up to 5 days per week) for 9 months

Placebo: with each exercise session (up to 5 days per week) for 9 months

musculoskeletal-loading exercise: Exercise training program designed to increase bone and muscle mass, including weight lifting and weight-bearing exercises such as jumping in place and treadmill walking up to 5 days per week for 9 months


Participant Flow:   Overall Study
    Placebo Pre and Post Exercise   Ibuprofen Pre and Placebo Post Exercise   Placebo Pre and Ibuprofen Post Exercise
STARTED   50   55   54 
COMPLETED   37   51   42 
NOT COMPLETED   13   4   12 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Placebo Pre and Post Exercise

placebo before and after musculoskeletal-loading exercise

Placebo: with each exercise session (up to 5 days per week) for 9 months

musculoskeletal-loading exercise: Exercise training program designed to increase bone and muscle mass, including weight lifting and weight-bearing exercises such as jumping in place and treadmill walking up to 5 days per week for 9 months

Ibuprofen Pre and Placebo Post Exercise

ibuprofen before and placebo after musculoskeletal-loading exercise

Ibuprofen: 400 mg with each exercise session (up to 5 days per week) for 9 months

Placebo: with each exercise session (up to 5 days per week) for 9 months

musculoskeletal-loading exercise: Exercise training program designed to increase bone and muscle mass, including weight lifting and weight-bearing exercises such as jumping in place and treadmill walking up to 5 days per week for 9 months

Placebo Pre and Ibuprofen Post Exercise

placebo before and ibuprofen after musculoskeletal-loading exercise

Ibuprofen: 400 mg with each exercise session (up to 5 days per week) for 9 months

Placebo: with each exercise session (up to 5 days per week) for 9 months

musculoskeletal-loading exercise: Exercise training program designed to increase bone and muscle mass, including weight lifting and weight-bearing exercises such as jumping in place and treadmill walking up to 5 days per week for 9 months

Total Total of all reporting groups

Baseline Measures
   Placebo Pre and Post Exercise   Ibuprofen Pre and Placebo Post Exercise   Placebo Pre and Ibuprofen Post Exercise   Total 
Overall Participants Analyzed 
[Units: Participants]
 37   51   42   130 
Age 
[Units: Years]
Mean (Standard Deviation)
 64  (4)   64  (4)   66  (4)   64  (4) 
Gender 
[Units: Participants]
       
Female   23   32   27   82 
Male   14   19   15   48 
Ethnicity (NIH/OMB) 
[Units: Participants]
       
Hispanic or Latino   2   2   1   5 
Not Hispanic or Latino   35   49   41   125 
Unknown or Not Reported   0   0   0   0 
Race (NIH/OMB) 
[Units: Participants]
       
American Indian or Alaska Native   0   1   1   2 
Asian   1   1   1   3 
Native Hawaiian or Other Pacific Islander   0   0   0   0 
Black or African American   0   2   5   7 
White   33   47   35   115 
More than one race   3   0   0   3 
Unknown or Not Reported   0   0   0   0 
Region of Enrollment 
[Units: Participants]
       
United States   37   51   42   130 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Percentage Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at 9 Months   [ Time Frame: Baseline and after 9 months of training ]

2.  Primary:   Percentage Change From Baseline in Total Hip Bone Mineral Density (BMD) at 9 Months   [ Time Frame: Baseline and after 9 months of training ]

3.  Primary:   Change From Baseline in Fat-free Mass at 9 Months   [ Time Frame: Baseline and after 9 months of training ]

4.  Secondary:   Percentage Change From Baseline in Femoral Neck Bone Mineral Density (BMD) at 9 Months   [ Time Frame: Baseline and after 9 months of training ]

5.  Secondary:   Percentage Change From Baseline in Trochanter Bone Mineral Density (BMD) at 9 Months   [ Time Frame: Baseline and after 9 months of training ]

6.  Secondary:   Percentage Change From Baseline in Sub-trochanter Bone Mineral Density (BMD) at 9 Months   [ Time Frame: Baseline and after 9 months of training ]

7.  Secondary:   Change in Thigh Cross-sectional Muscle Area   [ Time Frame: Baseline and after 9 months of training ]

8.  Secondary:   Bone Turnover Markers   [ Time Frame: Baseline, and after 4.5 & 9 months of training ]

9.  Secondary:   Expression of Selected Proteins and Genes Associated With Muscle Build-up and Breakdown   [ Time Frame: Baseline and after 9 months of training ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data

The study did not include a no-exercise control group. The variability in the BMD responses was greater than expected.

The results may be specific to ibuprofen and not to other NSAIDs.



  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Catherine Jankowski
Organization: University of Colorado Anschutz Medical Campus
phone: 303-724-7383
e-mail: catherine.jankowski@ucdenver.edu


Publications:

Responsible Party: University of Colorado, Denver
ClinicalTrials.gov Identifier: NCT00462722     History of Changes
Other Study ID Numbers: 06-0769
R01AG018857 ( US NIH Grant/Contract Award Number )
Study First Received: April 17, 2007
Results First Received: June 11, 2015
Last Updated: October 7, 2015
Health Authority: United States: Federal Government